Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 22, 2026, 9:53 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Enteropathy Clear all
Completed No phase listed Observational Accepts healthy volunteers

Malnutrition Associated With Complications After Ileostomy Reversal

NCT03909542
View directory record Official record
Conditions
Inflammatory Bowel Diseases, Ileostomy
Interventions
Not listed
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
Not listed
Enrollment
359 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2018
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 9, 2019 · Synced Jul 22, 2026, 9:53 PM EDT
Completed No phase listed Observational

TICAP - Titanium Clips for Appendiceal Stump Closure

NCT01734837
View directory record Official record
Conditions
Appendicitis
Interventions
DS-Ligature Clip
Device
Lead sponsor
Aesculap AG
Industry
Eligibility
16 Years and older
Enrollment
390 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
2
States / cities
Marina del Rey, California • Bethlehem, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 8, 2015 · Synced Jul 22, 2026, 9:53 PM EDT
Completed Phase 2 Interventional

Monoclonal Antibody Plus Chemotherapy in Treating Patients With Advanced Colorectal Cancer That Overexpresses HER2

NCT00003995
View directory record Official record
Conditions
Colorectal Cancer
Interventions
trastuzumab, irinotecan hydrochloride
Biological · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Not listed
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1999
U.S. locations
5
States / cities
The Bronx, New York • Pittsburgh, Pennsylvania • Providence, Rhode Island + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 7, 2013 · Synced Jul 22, 2026, 9:53 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Redes III Patient Navigator Qol Study

NCT02275754
View directory record Official record
Conditions
Breast Cancer, Prostate Cancer, Colorectal Cancer
Interventions
PN+LCNC, PN Only
Behavioral
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2017
U.S. locations
2
States / cities
Chicago, Illinois • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Oct 1, 2018 · Synced Jul 22, 2026, 9:53 PM EDT
Completed Phase 1 Interventional

Irinotecan and Alisertib in Treating Patients With Advanced Solid Tumors or Colorectal Cancer

NCT01923337
View directory record Official record
Conditions
Mucinous Adenocarcinoma of the Colon, Mucinous Adenocarcinoma of the Rectum, Recurrent Colon Cancer, Recurrent Rectal Cancer, Signet Ring Adenocarcinoma of the Colon, Signet Ring Adenocarcinoma of the Rectum, Stage IIIA Colon Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
irinotecan hydrochloride, alisertib
Drug
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Jan 3, 2019 · Synced Jul 22, 2026, 9:53 PM EDT
Enrolling by invitation Not applicable Interventional

Head to Head Trial of Mailed Cologuard to Mailed FIT

NCT06931860
View directory record Official record
Conditions
Colorectal Cancer Screening, Fecal Immunochemical Test, Multi-target Stool DNA, Colorectal Cancer (CRC)
Interventions
Cologuard, Fecal Immunochemical Test
Diagnostic Test
Lead sponsor
University of California, San Diego
Other
Eligibility
45 Years to 49 Years
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Sep 8, 2025 · Synced Jul 22, 2026, 9:53 PM EDT
Completed Phase 2 Interventional

Isolated Hepatic Perfusion With Melphalan Followed By Chemotherapy in Treating Patients With Unresectable Colorectal Cancer That is Metastatic to the Liver

NCT00019760
View directory record Official record
Conditions
Recurrent Colon Cancer, Liver Metastases, Stage IV Rectal Cancer, Recurrent Rectal Cancer, Stage IV Colon Cancer
Interventions
floxuridine, leucovorin calcium, melphalan
Drug
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
Not listed
Timeline
1999 – 2002
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 30, 2023 · Synced Jul 22, 2026, 9:53 PM EDT
Active, not recruiting Phase 2 Interventional

Circulating Cell-Free Tumor DNA Testing in Guiding Treatment for Patients With Advanced or Metastatic Colorectal Cancer

NCT03844620
View directory record Official record
Conditions
Refractory Colorectal Carcinoma, Stage III Colorectal Cancer AJCC v8, Stage IIIA Colorectal Cancer AJCC v8, Stage IIIB Colorectal Cancer AJCC v8, Stage IIIC Colorectal Cancer AJCC v8, Stage IV Colorectal Cancer AJCC v8, Stage IVA Colorectal Cancer AJCC v8, Stage IVB Colorectal Cancer AJCC v8, Stage IVC Colorectal Cancer AJCC v8
Interventions
Best Practice, Laboratory Procedure, Quality-of-Life Assessment, Questionnaire Administration, Regorafenib, Trifluridine and Tipiracil Hydrochloride
Other · Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 15, 2026 · Synced Jul 22, 2026, 9:53 PM EDT
Completed Not applicable Interventional

Prevention of Ileus After Gynecologic Surgery Using Chewing Gum

NCT00831246
View directory record Official record
Conditions
Ileus
Interventions
chewing gum - Extra Winterfresh, Standard Post-Op Care
Other
Lead sponsor
Aultman Health Foundation
Other
Eligibility
18 Years and older · Female only
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Canton, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 20, 2018 · Synced Jul 22, 2026, 9:53 PM EDT
Completed No phase listed Observational

A Long Term Safety Study of Infliximab (Remicade) in in Ulcerative Colitis Patients

NCT00207688
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
Infliximab 5 mg/kg, Infliximab 10 mg/kg, Placebo
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
Not listed
Enrollment
505 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2015
U.S. locations
44
States / cities
Scottsdale, Arizona • Anaheim, California • Los Angeles, California + 41 more
Source: ClinicalTrials.gov public record
Updated Jul 5, 2018 · Synced Jul 22, 2026, 9:53 PM EDT
Completed Phase 2 Interventional Results available

S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery

NCT03365882
View directory record Official record
Conditions
Colon Adenocarcinoma, ERBB2 Gene Amplification, Rectal Adenocarcinoma, Recurrent Colon Carcinoma, Recurrent Rectal Carcinoma, Stage III Colon Cancer AJCC v7, Stage III Rectal Cancer AJCC v7, Stage IIIA Colon Cancer AJCC v7, Stage IIIA Rectal Cancer AJCC v7, Stage IIIB Colon Cancer AJCC v7, Stage IIIB Rectal Cancer AJCC v7, Stage IIIC Colon Cancer AJCC v7, Stage IIIC Rectal Cancer AJCC v7, Stage IV Colon Cancer AJCC v7, Stage IV Rectal Cancer AJCC v7, Stage IVA Colon Cancer AJCC v7, Stage IVA Rectal Cancer AJCC v7, Stage IVB Colon Cancer AJCC v7, Stage IVB Rectal Cancer AJCC v7
Interventions
Cetuximab, Irinotecan Hydrochloride, Laboratory Biomarker Analysis, Pertuzumab, Trastuzumab, HER-2 testing
Biological · Drug · Other + 1 more
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years and older
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2025
U.S. locations
786
States / cities
Anchorage, Alaska • Fairbanks, Alaska • Goodyear, Arizona + 501 more
Source: ClinicalTrials.gov public record
Updated Feb 9, 2026 · Synced Jul 22, 2026, 9:53 PM EDT
Active, not recruiting Phase 3 Interventional

A Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Crohn's Disease Who Completed the Studies M14-431 or M14-433

NCT03345823
View directory record Official record
Conditions
Crohn's Disease
Interventions
Upadacitinib, Placebo for Upadacitinib
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 75 Years
Enrollment
747 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
123
States / cities
Mobile, Alabama • Chandler, Arizona • Scottsdale, Arizona + 97 more
Source: ClinicalTrials.gov public record
Updated Apr 8, 2026 · Synced Jul 22, 2026, 9:53 PM EDT
Completed Phase 4 Interventional

Stress Ulcer Prophylaxis Versus Placebo in Critically Ill Infants With Congenital Heart Disease

NCT03667703
View directory record Official record
Conditions
Congenital Heart Disease, Upper Gastrointestinal Bleeding, Stress Ulcer, Infection
Interventions
Famotidine, Placebo
Drug
Lead sponsor
Boston Children's Hospital
Other
Eligibility
1 Minute to 12 Months
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 20, 2022 · Synced Jul 22, 2026, 9:53 PM EDT
Completed Phase 1Phase 2 Interventional Results available

A Phase I/II Study of Pexa-Vec Oncolytic Virus in Combination With Immune Checkpoint Inhibition in Refractory Colorectal Cancer

NCT03206073
View directory record Official record
Conditions
Colorectal Cancer, Colorectal Carcinoma, Colorectal Adenocarcinoma, Refractory Cancer, Colorectal Neoplasms
Interventions
Durvalumab, Tremelimumab, Pexa-Vec
Drug · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 23, 2023 · Synced Jul 22, 2026, 9:53 PM EDT
Terminated Phase 2 Interventional Results available

A Study of Vobramitamab Duocarmazine in Participants With Metastatic Castration Resistant Prostate Cancer and Other Solid Tumors

NCT05551117
View directory record Official record
Conditions
Castration-Resistant Prostatic Cancer, Androgen-Independent Prostatic Cancer, Androgen-Insensitive Prostatic Cancer, Androgen-Resistant Prostatic Cancer, Hormone Refractory Prostatic Cancer, Anal Cancer, Anal Neoplasm, Carcinoma, Squamous Cell of Head and Neck, Head and Neck Squamous Cell Carcinoma, Laryngeal Squamous Cell Carcinoma, Oral Squamous Cell Carcinoma, Malignant Melanoma, Melanoma, Non-small Cell Lung Cancer, Non-small Cell Carcinoma, Small-cell Lung Cancer, Small Cell Carcinoma
Interventions
vobramitamab duocarmazine 2.0 mg (Arm A), vobramitamab duocarmazine 2.7 mg (Arm B), vobramitamab duocarmazine, Abiraterone, Enzalutamide
Biological · Drug
Lead sponsor
MacroGenics
Industry
Eligibility
18 Years and older
Enrollment
192 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
14
States / cities
Fountain Valley, California • Los Angeles, California • Jacksonville, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Feb 8, 2026 · Synced Jul 22, 2026, 9:53 PM EDT
Withdrawn Phase 1 Interventional

Randomized Trial Comparing Single vs. Maintenance Fecal Microbiota Transplant for Refractory Crohn's Disease in Children

NCT03747718
View directory record Official record
Conditions
Crohn Disease
Interventions
Fecal Microbiota Transplantation, Placebo
Biological · Other
Lead sponsor
Stanford University
Other
Eligibility
2 Years to 25 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Apr 13, 2023 · Synced Jul 22, 2026, 9:53 PM EDT
Not listed No phase listed Observational Accepts healthy volunteers

Cultured Circulating Tumor Cells in Prostate and Other Cancers

NCT02123862
View directory record Official record
Conditions
Prostate Cancer
Interventions
Not listed
Lead sponsor
Oscar Goodman, Jr.
Other
Eligibility
18 Years and older
Enrollment
220 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2018
U.S. locations
1
States / cities
Las Vegas, Nevada
Source: ClinicalTrials.gov public record
Updated Jan 18, 2015 · Synced Jul 22, 2026, 9:53 PM EDT
Completed Phase 2 Interventional Results available

Capecitabine and Temozolomide for Neuroendocrine Cancers

NCT00869050
View directory record Official record
Conditions
Neuroendocrine Tumors
Interventions
Capecitabine, Temozolomide
Drug
Lead sponsor
Columbia University
Other
Eligibility
18 Years to 80 Years
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2014
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 24, 2016 · Synced Jul 22, 2026, 9:53 PM EDT
Terminated Phase 3 Interventional

The Efficacy and Safety of Cobitolimod in Participants With Moderate to Severe Active Left-Sided Ulcerative Colitis

NCT04985968
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
Cobitolimod 250 mg, Cobitolimod 500 mg, Placebo
Drug
Lead sponsor
InDex Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
171 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
25
States / cities
Granada Hills, California • Mission Viejo, California • Rancho Cucamonga, California + 17 more
Source: ClinicalTrials.gov public record
Updated Dec 26, 2023 · Synced Jul 22, 2026, 9:53 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Colorectal Cancer Screening Intervention Study

NCT06424197
View directory record Official record
Conditions
Colorectal Cancer
Interventions
Racial group-targeted messages, Explicit Commitment
Other
Lead sponsor
Oakland University
Other
Eligibility
45 Years to 80 Years
Enrollment
799 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Rochester, Michigan
Source: ClinicalTrials.gov public record
Updated Aug 7, 2025 · Synced Jul 22, 2026, 9:53 PM EDT
Completed Phase 1 Interventional

Bevacizumab, Erlotinib, and Capecitabine for Locally Advanced Rectal Cancer

NCT00543842
View directory record Official record
Conditions
Rectal Cancer
Interventions
Bevacizumab, Capecitabine, Erlotinib, Radiation Therapy, Surgery
Drug · Radiation · Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 25, 2015 · Synced Jul 22, 2026, 9:53 PM EDT
Active, not recruiting Early Phase 1 Interventional

An Investigational Scan (64Cu-Labeled M5A Antibody) in Combination With SOC Chemotherapy and Radiotherapy in Locally Advanced Rectal Cancer

NCT05245786
View directory record Official record
Conditions
Locally Advanced Rectal Carcinoma, Stage III Rectal Cancer AJCC v8, Stage IIIA Rectal Cancer AJCC v8, Stage IIIB Rectal Cancer AJCC v8, Stage IIIC Rectal Cancer AJCC v8
Interventions
Copper Cu 64 Anti-CEA Monoclonal Antibody M5A, Imaging Technique
Biological · Procedure
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Jun 7, 2026 · Synced Jul 22, 2026, 9:53 PM EDT
Completed Not applicable Interventional Results available

Safety and Efficacy Study of HET Bipolar System for Treatment of Stage I and Stage II Hemorrhoids

NCT01841970
View directory record Official record
Conditions
Hemorrhoids, Internal
Interventions
HET Bipolar System
Device
Lead sponsor
Medtronic - MITG
Industry
Eligibility
21 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 15, 2017 · Synced Jul 22, 2026, 9:53 PM EDT
Recruiting Phase 3 Interventional

A Clinical Study of Calderasib (MK-1084) With Targeted Therapy and Chemotherapy in People With Colorectal Cancer (MK-1084-012/KANDLELIT-012)

NCT06997497
View directory record Official record
Conditions
Colon Adenocarcinoma, Rectal Adenocarcinoma
Interventions
Calderasib, Oxaliplatin, Leucovorin/levofolinate calcium, 5-Fluorouracil, Cetuximab, Bevacizumab, Bevacizumab biosimilar
Drug · Biological
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
477 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
31
States / cities
Los Angeles, California • Fort Collins, Colorado • Lone Tree, Colorado + 27 more
Source: ClinicalTrials.gov public record
Updated Jul 19, 2026 · Synced Jul 22, 2026, 9:53 PM EDT